Amgen, GSK Urge Justices To Allow Patents On Genus Claims
By Dani Kass (November 17, 2020, 9:23 PM EST) -- Amgen, GlaxoSmithKline and a group of intellectual property professors have urged the U.S. Supreme Court to take up Merck & Co.'s petition asking the justices to ensure companies can patent genus claims, warning that the future of innovation is on the line.
The trio of amicus briefs filed Monday say the Federal Circuit has made patenting genus claims nearly impossible, which fundamentally ignores how scientific discovery occurs in the chemical, pharmaceutical and biotech industries. The professors said the petition filed by Merck unit Idenix Pharmaceuticals LLC in September is a "strong vehicle" to settle this pressing issue.
Idenix is trying to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!